Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers

Documenti analoghi

• Effects of a High‐Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia
  di: Hengbang Wang, et al.
  Pubblicazione: (2026)
• The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239
  di: Christine Huynh, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
  di: Tianxing Liu, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
  di: Jia‐yu Zhang, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
  di: Huijun Chen, et al.
  Pubblicazione: (2024)